Active	Status	Sponsor type	Region	Phase	Filter
7 Active 3 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Barone, Paolo
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33
Ainscough, Susan
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33